Credit Suisse Starts Progenics Pharmaceuticals (PGNX) at Outperform

December 7, 2018 5:45 AM EST
Get Alerts PGNX Hot Sheet
Price: $4.10 --0%

Rating Summary:
    8 Buy, 2 Hold, 0 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 17 | Down: 5 | New: 36
Trade Now! 
Join SI Premium – FREE

Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.

Credit Suisse initiates coverage on Progenics Pharmaceuticals (NASDAQ: PGNX) with a Outperform rating and a price target of $6.50.

For an analyst ratings summary and ratings history on Progenics Pharmaceuticals click here. For more ratings news on Progenics Pharmaceuticals click here.

Shares of Progenics Pharmaceuticals closed at $4.73 yesterday.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

New Coverage

Related Entities

Credit Suisse